spacer
home > ict > spring 2020 > the future awaits us
PUBLICATIONS
International Clinical Trials

The Future Awaits Us






EPC: In Medical Writing – A Bold New Path: The Future Awaits Us, Lisa A Cloutier at Janssen Research & Development discusses outsourcing trends in medical writing. What do you think the future will hold for medical writing services?

Barry Drees: I have been in medical writing for over 30 years, and it seems that every five years or so, the outsourcing trend pendulum swings back and forth between ‘everything should be done in-house’ and ‘virtual company: outsource everything’. I believe that the ideal solution is somewhere in the middle, where a company maintains a core of medical writing experience but uses outside contractors in times of peak demand (such as large submissions) or for specialist expertise. So, I see a very secure future for contract medical writers.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the author

Barry Drees received his PhD in Molecular Genetics at the University of California, US. Following his postdoctoral work as a fellow of the National Institute of Health, he worked as a Medical Writer at Hoechst/Aventis for 12 years. Barry is a frequent speaker on medical writing, statistics, and other scientific communication topics for a number of associations and companies in the pharma industry. He is a past President of the European Medical Writers Association (EMWA) and is a former Editorin- Chief of the EMWA journal. He is currently a Co-Founder and Senior Partner of Trilogy Writing & Consulting, continuing to personally lead submission teams and provide training for the industry around the world.
Print this page
Send to a friend
Privacy statement
News and Press Releases

PHARMA.AERO To Organize The Second International Masterclass On Pharma Logistics In 2022

Abu Dhabi has set its sights on Belgium, as a leading global pharmaceutical hub, to establish a global distribution corridor to serve the world in vaccine delivery and future life science needs. The collaboration builds on the capabilities of Abu Dhabi’s healthcare sector as a leading life sciences hub and the efforts of the HOPE Consortium in providing vaccine solutions for the world.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement